中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (38): 7135-7139.doi: 10.3969/j.issn.2095-4344.2012.38.022

• 药物控释材料 drug delivery materials • 上一篇    下一篇

微囊化PC12细胞蛛网膜下腔移植治疗慢性神经源性疼痛

伍少玲，马 超，栗 晓   

  1. 中山大学孙逸仙纪念医院康复科，广东省广州市 510120
  • 收稿日期:2012-01-13 修回日期:2012-05-27 出版日期:2012-09-16 发布日期:2012-09-16
  • 通讯作者: 马超，主任医师，中山大学孙逸仙纪念医院康复科，广东省广州市 510120 ma_chao99@126.com
  • 作者简介:伍少玲☆，女，1974年生，广东省新会市人，汉族，2009年中山大学康复医学与理疗学专业毕业，博士，副主任医师，硕士生导师，主要从事疼痛的临床诊疗与基础研究。 wushaolinggz@126.com

Subarachnoid implantation of microencapsulated PC12 cells reduces cold allodynia in a rat model of neuropathic pain

Wu Shao-ling, Ma Chao, Li Xiao   

  1. Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China
  • Received:2012-01-13 Revised:2012-05-27 Online:2012-09-16 Published:2012-09-16
  • Contact: Ma Chao, Chief physician, Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China ma_chao99@126.com
  • About author:Wu Shao-ling☆, Doctor, Associate chief physician, Master’s supervisor, Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China wushaolinggz@126.com

PDF

604

被引次数

3

摘要：

背景：大量动物实验已证实，微囊化嗜铬细胞蛛网膜下腔移植具有镇痛作用，但由于异体移植存在伦理学的广泛争议，而人肾上腺嗜铬细胞来源匮乏，因此，必须寻求一种新的、可合成和释放脑啡肽等物质，且来源丰富的细胞用于移植镇痛研究。
目的：观察微囊化PC12细胞移植入慢性神经源性疼痛模型大鼠蛛网膜下腔后的镇痛效果。
方法：将慢性坐骨神经缩窄性损伤模型鼠随机数字表法分为3组，造模后1周进行移植。微囊化PC12细胞组、裸PC12细胞组、空微囊组分别取微囊包裹后第3-5天的微囊化PC12细胞悬液、PC12细胞悬液、APA空微囊悬液植入大鼠蛛网膜下腔。
结果与结论：微囊化PC12细胞组大鼠在移植后各时间点，两侧后肢收缩次数和时间的差值与移植前相比显著下降(P < 0.01)，组间比较其差值均低于裸PC12细胞组和空微囊组(P < 0.01)；在移植后第7周，微囊化PC12细胞组大鼠脑脊液中脑啡肽和去甲肾上腺素的浓度显著高于裸PC12细胞组和空微囊组(P < 0.01)。提示微囊化PC12细胞蛛网膜下腔移植可有效缓解慢性坐骨神经缩窄性损伤模型鼠在冷致痛实验中的痛觉过敏现象，同时，大鼠脑脊液中脑啡肽和去甲肾上腺素的水平相应升高。

关键词: PC12细胞, 微囊, 细胞移植, 镇痛, 慢性坐骨神经缩窄性损伤, 脑啡肽, 去甲肾上腺素

Abstract:

BACKGROUND: Many studies have confirmed that the subarachnoid implantation of microencapsulated adrenal chromaffin cells can relieve chronic pain in rodent models. An ethical argument surrounds the implantation of animal (xenogenic) adrenal chromaffin cells for human pain therapy, and the availability of human chromaffin cells is very limited. Thus, a new source of cells must be explored for cellular transplantation in pain therapy.
OBJECTIVE: To investigate the potential of microencapsulated PC12 cells to improve cold allodynia in a rat model of chronic neuropathic pain.
METHODS: Thirty-six Spraque Dawley rats with chronic constrictive injury were divided randomly into three groups: alginic-polylysine-alginic (APA) microencapsulated PC12 cell group, bare PC12 group and empty capsule group. The subarachnoid implantation was performed at 3-5 days after microcapsulation.
RESULTS AND CONCLUSION: After transplanted with APA-PC12, the difference in retracted frequency and time between two hind legs of rats was significantly decreased which compared with the results pre-transplantation (P < 0.01). Meanwhile, the differences were significantly lower than those in the bare PC12 group and empty capsule group (P < 0.01). The levels of met-enkephalin and norepinephrine in the cerebrospinal fluid of rats in the APA-PC12 group were significantly higher than those in the bare PC12 group and empty capsule group (P < 0.01) at week 7 after transplantation. These results suggest that subarachnoid implantation of microencapsulated PC12 cells can suppress cold allodynic behavior in a rat model of neuropathic pain. Increased levels of met-enkephalin and norepinephrine are found in the cerebrospinal fluid.

中图分类号: